[144] Snowflake Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.

Transaction details: The shares were granted as restricted stock units (RSUs) under the company’s 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.

Post-transaction ownership: Following the award, DeFord’s beneficial ownership rises to 159,185 shares, all held directly.

Implications: A director increasing his stake—albeit via equity compensation—tends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI’s long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.

Positive

• Director ownership increases by 89,139 shares, raising total holdings to 159,185 and enhancing alignment with shareholders.
• Equity award vests within one year, encouraging near-term board engagement and retention.

Negative

• None.

Insights

Equity Analyst

TL;DR: Director received 89k RSUs, boosting stake to 159k shares; signals alignment but no cash purchase.

From a capital-markets standpoint, DeFord’s RSU grant modestly increases insider ownership, which many investors view as a governance positive. The transaction adds ~0.07% to MRVI’s 135 million share count—immaterial for dilution—but confirms ongoing use of equity incentives to attract and retain leadership. Given the $2.16 reference price, the award value is roughly $192k, a small expense relative to MRVI’s market cap. Because the filing shows a code "A" rather than "P," the acquisition is not an open-market buy and therefore carries less immediate signaling power. Overall impact: mildly constructive.

Corporate Governance Specialist

TL;DR: Fresh RSU grant under 2020 Plan ties director compensation to performance; limited dilution, neutral financial impact.

The one-year/next-AGM vesting schedule promotes short-term board retention while still aligning incentives with shareholder returns through equity-based pay. No indicators of insider selling or material governance concerns are present. As the award is routine under an approved plan, it is unlikely to shift voting dynamics or trigger proxy advisory scrutiny.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	25000	5621000.00	333700000	06/30/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	06/30/2025	Option Granted - 02/08/2017	Issuer			25000	06/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	04/09/2025	6250	937500.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	04/23/2025	6250	937500.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	05/01/2025	6250	1050000.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	05/08/2025	31250	5468750.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	05/15/2025	12500	2250000.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	06/10/2025	548	115058.08
Benoit Dageville Suite 3A, 106 East Babcock Street Bozeman MT 59715	Class A	06/17/2025	1912	397696.00
Benoit Dageville Suite 3A 106 East Babcock Street Bozeman MT 59715	Class A	06/23/2025	870	182586.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many MRVI shares did director John A. DeFord acquire on 16 June 2025?

He received 89,139 restricted stock units of Class A common stock.

What is John A. DeFord’s total beneficial ownership in MRVI after the transaction?

Following the grant, DeFord beneficially owns 159,185 shares directly.

When do the newly granted MRVI RSUs vest?

The RSUs vest in full on the earlier of one year from 16 Jun 2025 or the 2026 annual shareholder meeting.

Was the acquisition an open-market purchase?

No. The Form 4 lists transaction code "A," indicating an equity grant rather than a market purchase.

What was the reference price assigned to the RSUs in the Form 4?

The filing reports a $2.16 price per share for valuation purposes.